Human Subjects Research

Human subjects research in genetics raises unique ethical considerations around informed consent, return of research results, privacy of genetic data, and the historical exploitation of vulnerable populations. Genetic counselors must understand the regulatory framework governing research and the ethical principles underlying it, particularly as the boundary between research and clinical care becomes increasingly blurred.

• Institutional Review Board (IRB): An independent committee that reviews, approves, and monitors research involving human subjects. The IRB ensures research protocols comply with federal regulations and ethical principles. All federally funded human subjects research must be reviewed by an IRB. Key IRB functions include reviewing informed consent documents, assessing risk-benefit ratios, ensuring equitable subject selection, and monitoring for adverse events.
• The Common Rule (45 CFR 46): The federal regulation governing human subjects research. Revised in 2018, it applies to all federally funded research and many institutions apply it to all research regardless of funding. Key provisions include requirements for informed consent, IRB review, and protections for vulnerable populations (children, prisoners, pregnant women). The 2018 revision introduced broad consent, allowing subjects to consent to unspecified future research use of stored biospecimens and data.
• Belmont Report (1979): The foundational document for research ethics in the United States, produced by the National Commission for the Protection of Human Subjects. It establishes three core principles:
  • Respect for persons: Individuals should be treated as autonomous agents, and persons with diminished autonomy (children, cognitively impaired individuals) deserve additional protections. In practice, this means informed consent and the right to withdraw.
  • Beneficence: Researchers must maximize benefits and minimize harms to participants. This involves careful risk-benefit analysis and study design that protects subjects.
  • Justice: The benefits and burdens of research should be distributed fairly. No population should be disproportionately recruited because of convenience or vulnerability, and research benefits should flow back to the communities that participate.
• Informed consent in research vs. clinical care: Research consent differs from clinical consent in several important ways. Research consent must disclose that the activity is research (not treatment), describe the purpose and procedures, explain that participation is voluntary and can be withdrawn without penalty, identify foreseeable risks, and describe any benefits. Unlike clinical consent, research consent must address the possibility that the study may not benefit the participant directly.
• Return of results in research: A major ongoing debate. Should researchers return individual genetic results (especially medically actionable findings) to research participants? Arguments in favor cite beneficence and respect for persons; arguments against cite the distinction between research and clinical-grade testing (research assays may not meet CLIA standards), the burden on researchers, and the potential for harm from unvalidated results. Current consensus (per ACMG and NHGRI) favors returning results that are analytically valid, clinically significant, and actionable, ideally after confirmation in a CLIA-certified lab.
• ELSI (Ethical, Legal, and Social Implications): The ELSI Research Program was established alongside the Human Genome Project to study the ethical, legal, and social implications of genomic research. ELSI topics include genetic privacy, discrimination, informed consent for genomic data sharing, community engagement, and the impact of genetics on concepts of race and identity. ELSI is funded by NHGRI and has shaped policy on issues from GINA to biobank governance.
• Biobanks and data sharing: Large-scale biobanks (UK Biobank, All of Us, ClinVar) collect and share genetic data for research. Ethical considerations include consent models (broad consent vs. specific consent vs. tiered consent), re-identification risk (genetic data is inherently identifiable), governance structures, and benefit-sharing with contributing communities.
• Historical abuses: The Tuskegee Syphilis Study (1932-1972) is the most cited example of research ethics violations in the U.S., directly leading to the Belmont Report. In genetics, the Havasupai case (2004) involved misuse of DNA samples collected from a Native American tribe for diabetes research: the samples were used without consent for studies on schizophrenia, migration, and inbreeding, violating the community's trust and cultural values. The Henrietta Lacks case raised issues about consent, commercialization of biological materials, and racial justice.
• Certificate of Confidentiality: Issued by NIH, these certificates protect researchers from being compelled to disclose identifiable research information in legal proceedings. Important for genetic research, where disclosure of results could have implications for insurance and employment.

• A researcher discovers a pathogenic BRCA1 variant in a participant enrolled in a population genomics study. The assay used is a research-grade platform, not CLIA-certified. The appropriate course is to offer the participant the opportunity to learn the result, and if they choose to know, recommend confirmation in a CLIA-certified clinical laboratory before any medical action is taken.
• A genetic counselor is asked to help recruit patients from a sickle cell clinic for a gene therapy trial. All patients at this clinic are Black. The counselor should consider justice: is this population being recruited because it is scientifically appropriate (sickle cell is prevalent in this community) or because it is convenient? Are the potential benefits of the therapy likely to be accessible and affordable to this community? Is the consent process culturally appropriate?
• A patient in your clinical practice mentions she is enrolled in a research study and received a "research result" showing a variant in a cardiomyopathy gene. She asks you what to do. Counsel her that research results are not validated for clinical use and recommend clinical-grade confirmatory testing in a CLIA-certified lab before any changes to her medical management.
• A biobank participant withdraws consent and asks for their samples to be destroyed. Under the revised Common Rule, participants have the right to withdraw. However, data already analyzed and de-identified may not be retrievable. The scope of withdrawal should be defined in the original consent document.